"Substantia Nigra" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.
| Descriptor ID |
D013378
|
| MeSH Number(s) |
A08.186.211.132.659.413.656
|
| Concept/Terms |
Substantia Nigra- Substantia Nigra
- Nigra, Substantia
- Nigras, Substantia
- Substantia Nigras
|
Below are MeSH descriptors whose meaning is more general than "Substantia Nigra".
Below are MeSH descriptors whose meaning is more specific than "Substantia Nigra".
This graph shows the total number of publications written about "Substantia Nigra" by people in this website by year, and whether "Substantia Nigra" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Substantia Nigra" by people in Profiles.
-
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
-
Protein kinase Cd upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. Neurobiol Dis. 2016 09; 93:96-114.
-
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis. 2015 Jan; 73:70-82.
-
The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem. 2013 Jul 26; 288(30):21955-71.
-
Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem. 2013 Jul 19; 288(29):20843-20855.
-
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012 Sep; 11(6):768-73.
-
a-Synuclein negatively regulates protein kinase Cd expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci. 2011 Feb 09; 31(6):2035-51.
-
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009 Oct 28; 29(43):13543-56.
-
Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci. 2009 Feb 18; 29(7):1962-76.
-
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007 Dec; 21(14):3835-44.